The utilisation of ctDNA approaches for residual disease detection during neoadjuvant and perioperative immunotherapy in oesophagogastric cancers

Ronan J. Kelly; Valsamo Anagnostou; Vincent K. Lam; Ali H. Zaidi

doi:10.1002/ctm2.70223

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (2) : e70223 DOI: 10.1002/ctm2.70223

COMMENTARY

The utilisation of ctDNA approaches for residual disease detection during neoadjuvant and perioperative immunotherapy in oesophagogastric cancers

Author information +

History +

PDF

Keywords

ctDNA / MRD / oesophageal cancer / precision medicine

Cite this article

Download citation ▾

Ronan J. Kelly,Valsamo Anagnostou,Vincent K. Lam,Ali H. Zaidi. The utilisation of ctDNA approaches for residual disease detection during neoadjuvant and perioperative immunotherapy in oesophagogastric cancers. Clinical and Translational Medicine, 2025, 15(2): e70223 DOI:10.1002/ctm2.70223

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Van Hagen P, Hulshof MCCM, Van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22): 2074-2084.

[2]	Hoeppner J, Brunner T, Lordick F, et al. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). J Clin Oncol. 2024; 42(17_suppl): LBA1.

[3]	Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021; 384(13): 1191-1203.

[4]	Kelly RJ, Bever K, Chao J, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. J Immunother Cancer. 2023; 11(6): e006658.

[5]	Kelly RJ, Landon BV, Zaidi AH, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024; 30(4): 1023-1034.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.